Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Company files expansive intellectual property protection for "Membrane Protein Factory" to produce purified and biologically active membrane proteins for drug development
公司对“膜蛋白工厂”进行了广泛的知识产权保护,生产纯化和生物活性的膜蛋白,用于药物开发。
External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 20301
外部资料显示,2022年全美GPCR市场年增长5%以上,价值近35亿美元,并将持续增长至2030年。1
PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (GPCRs).
2024年6月11日匹兹堡(全球新闻社)-Predictive Oncology Inc.(纳斯达克:POAI)宣布推出一种新技术,旨在表达功能稳定的G蛋白偶联受体(GPCRs),这是一种以人工智能驱动的药物发现和生物制品领域的领导者。
GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development2,3.
GPCR是突破细胞膜的受体,被认为在肿瘤发生中起着关键作用,先前的一些研究证明了它在癌症的起始、进展和转移中的作用。据估计,针对GPCR的药物在治疗药物全球市场中占据超过30%,然而已经表征的GPCR靶点仅占GPCR超家族的一小部分,因此还存在巨大的潜力来进一步研究GPCR的治疗靶点。2,3.
"As a result of our sustained efforts to develop this technology, Predictive Oncology has been able to file expansive intellectual property (IP) protection for its novel GPCR expression platform," said Dr. Larry DeLucas, SVP of Biologics for Predictive Oncology. "We believe that this technology will open significant partnering opportunities for our company, and we look forward to working with drug discovery and development companies that are targeting GPCRs to expand their portfolios and replenish their pipelines."
肿瘤预测公司的生物学高级副总裁拉里·德鲁卡斯博士表示:由于我们持续不断地开发这项技术,预测肿瘤学公司已经能够为其新型GPCR表达平台提供广泛的知识产权(IP)保护。我们相信,这项技术将为我们的公司带来重要的合作机会,我们期待与致力于扩大投资组合和补充其项目管道的药物开发公司合作。
Predictive Oncology plans to combine this proprietary GPCR expression system with its current High-Throughput Self-Interaction Chromatography (HSC) protein solubilization technology to enable the rapid identification of solution conditions that maintain purified GPCRs in a soluble and stable form. The company believes this can overcome many of the difficulties seen with existing expression technologies.
预测肿瘤计划将这种专有GPCR表达系统与其当前的高通量自交互色谱(HSC)蛋白质溶解技术相结合,以便快速确定维持纯化GPCR以溶解和稳定形式的溶液条件。该公司相信,这可以克服现有表达技术所遇到的许多困难。
"We are very pleased to introduce our new platform to potential pharma partners targeting GPCRs of interest," stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. "This technology represents a significant advancement over previous expression methodologies which, once launched later this year or in early 2025, will allow us to contribute to the advancement of new cancer therapeutics while tapping into a multi-billion-dollar annual market opportunity for GPCRs in the U.S. alone."
预测肿瘤公司的首席执行官雷蒙德·维纳尔表示:“我们非常高兴将这项新技术平台介绍给那些有兴趣针对GPCR开展研究的制药伙伴们。这项技术是相对于以往的表达方法的一个重要进展。我们相信,一旦在今年晚些时候或2025年初推出,我们将能够为新癌症治疗方法的推进做出贡献,同时也将在美国GPCR每年亿万美元的市场机会上分一杯羹。”
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.
医学预测正在积极推进利用人工智能和机器学习来加速早期药物发现,并为全球癌症患者获得药物开发提供支持。该公司经过科学验证的AI平台PADAL可以预测肿瘤样本对某种药物化合物的反应,准确率为92%,从而更加科学地选择药物/肿瘤类型组合,进行随后的体外测试。 还有,该公司拥有超过15万个可用于实验的异质性人类肿瘤样本的生物库,为学术界和行业伙伴提供了业界最广泛的基于人工智能的药物发现解决方案,进一步得到了完全拥有的CLIA实验室和GMP设施的支持。医学预测总部位于宾夕法尼亚州匹兹堡市。
预测肿瘤公司是人工智能和机器学习快速崛起的前沿领域之一,旨在通过科学验证的人工智能平台PEDAL以及150,000多个可测试的人类肿瘤细胞样本生物库为全球癌症患者进一步地药物开发及加速早期药物发现做出努力。公司拥有完整的CLIA实验室和GMP设施,其全面的基于人工智能的药物开发解决方案为学术界和行业合作伙伴提供了最广泛的选择。预测肿瘤公司总部设在宾夕法尼亚州匹兹堡市。
Investor Relations Contact
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
投资者关系联系人
剑桥金融合伙人Timothy McCarthy和医学预测的CEO Dr.Richard Gabriel。
领先的全球健康科技投行LifeSci Advisors LLC的合伙人Tim McCarthy:tim@lifesciadvisors.com
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
前瞻性声明:
本文发布中所讨论的某些问题包含了前瞻性声明。这些前瞻性声明反映了我们关于未来事件的当前期望和预测,并且受到我们的业务和投资所面临的重大风险,不确定性和假设的限制。除法律明确规定外,我们不承诺有意义或有义务更新这些前瞻性声明。我们在本新闻稿中提到的所有声明,除历史事实陈述外,均属于前瞻性声明,并涉及我们的战略、未来运营、未来财务状况、未来营收和财务表现、预计成本、前景、管理变更、管理计划和目标等方面。我们原计划将公告美国证监会“风险因素”下的因素,并同步发布项目公司的一部分文本和数据。
1Grand View Research. https://www.grandviewresearch.com/industry-analysis/g-protein-coupled-receptors-gpcrs-market;
2 Persistence Market Research: https//www.persistencemarketresearch.com/market-research/q-protein-coupled-receptors-market.asp
2 Persistence Market Research: https//www.persistencemarketresearch.com/market-research/q-protein-coupled-receptors-market.asp
3 https://pubmed.ncbi.nlm.nih.gov/34194261/
我们的董事会认为,我们的薪酬政策和实践是合理的,并适当地将我们的员工利益与股东的利益相一致。董事会认为,对于我们的高管和其他员工的激励性薪酬与收益挂钩的事实鼓励采取有利于公司短期和长期盈利的行动。此外,薪酬委员会审查有关我们的薪酬政策和实践的变化,以确保此类政策和实践不会鼓励我们的高管和其他员工采取可能导致公司出现重大不利影响的行动。https://pubmed.ncbi.nlm.nih.gov/34194261/